
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc demonstrates a strong potential for growth through its ongoing development of innovative treatments for diabetes and obesity, showcasing favorable clinical results for its lead candidate, icovamenib, which achieved a statistically significant reduction in HbA1c levels over a 52-week study period. The company continues to advance its pipeline, with the initiation of Phase I trials for BMF-650, an investigational oral GLP-1 receptor agonist that has shown promising preclinical results in weight reduction and glucose control. Additionally, Biomea Fusion's improved financial performance, indicated by a reduced net loss of $16.4 million for Q3 2025 compared to $32.8 million in Q3 2024, reflects efficient resource management and bolsters confidence in the company's future prospects.
Bears say
Biomea Fusion Inc. has reported a decrease in research and development expenses, falling from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may indicate a reduction in its investment in clinical trials and product development. General and administrative expenses also decreased from $6.8 million to $4.2 million during the same period, suggesting potential cost-cutting measures. Consequently, the company's revised price target reflects a downward adjustment from $16.00 to $12.00, raising concerns about its financial trajectory and growth potential.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares